Editorial board

  • M. Silbermann – MD, PhD, Prof., Middle East Cancer Consortium (Israel);
  • I. Azinovic – MD, A / Prof., IMOncology (Spain);
  • K. Narayan – MD, PhD, A / Prof., Peter MacCallum Cancer Center (Australia);
  • M. Gültekin – MD, Associate Prof., Turkish Ministry of Health (Turkey);
  • E. Imyanitov – MD, member-cor. RAS, Research Institute of Oncology named after N.N. Petrov (Russia);
  • V. Semiglazov – MD, prof., Member-cor. RAS, Research Institute of Oncology named after N.N. Petrov (Russia);
  • V. Moiseenko – MD, Prof., SPb State budgetary health care institution “Oncological Center” (Russia);
  • R. Orlova – MD, Clinical Hospital №122 named after. L.G. Sokolova (Russia);
  • M. Aliev – MD, prof., Acad. RAS, Research Institute of Pediatric Oncology and Hematology named after N.N. Blokhin (Russia);
  • I. Stilidi – MD, prof., Member-cor. RAS and Russian Academy of Medical Sciences, Russian Cancer Research Center named after N.N. Blokhin (Russia);
  • S. Krasnyi – MD, prof., Member-cor. NASB, RSPCOMR named after N.N. Aleksandrova (Belarus);
  • M. Dzhanzhaliya – MD, Prof., Cancer Center of Tbilisi (Georgia);
  • A. Tananyan – MD, Acad. RAMTS, National Cancer Center named after V.А.Fanarjian of the Ministry of Health (Armenia);
  • Z. Huseynov. – MD, ROSC (Tajikistan);
  • M. Tilliashaykhov – MD, ROSC MH (Uzbekistan);
  • B. Sultangaziyeva. – MD, prof., National Cancer Center (Kyrgyzstan);
  • L. Dzhansugurova – Cand. of med. Sciences, associate. Prof., Institute of General Genetics and Cytology (Kazakhstan);
  • I. Omarova – MD, prof., Karaganda ROD (Kazakhstan).